Arsenic Trioxide With or Without Ascorbic Acid in Treating Patients With Myelofibrosis [clinicaltrials:NCT01014546]

Bio2RDF uri

Arsenic Trioxide With or Without Ascorbic Acid in Treating Patients With Myelofibrosis [clinicaltrials:NCT01014546]

Clinical Study [clinicaltrials_vocabulary:Clinical-Study]

clinicaltrials resource [clinicaltrials_vocabulary:Resource]

http://bio2rdf.org/clinicaltrials:NCT01014546

Bio2RDF identifier

NCT01014546

http://www.w3.org/2001/XMLSchema#string

Bio2RDF namespace

clinicaltrials

http://www.w3.org/2001/XMLSchema#string

Bio2RDF uri

http://bio2rdf.org/clinicaltrials:NCT01014546

http://www.w3.org/2001/XMLSchema#string

brief summary [clinicaltrials_vocabulary:brief-summary]

This phase I trial stud ...... d may kill more cancer cells.

http://www.w3.org/2001/XMLSchema#string

brief title [clinicaltrials_vocabulary:brief-title]

Arsenic Trioxide With or Without Ascorbic Acid in Treating Patients With Myelofibrosis

http://www.w3.org/2001/XMLSchema#string

clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]

Adverse events, and their attribution throughout the study Up to 30 days post-treatment [clinicaltrials_resource:13f838822a6d3eb3fa9ba3a19231170f]

Adverse events, and their attribution throughout the study Up to 30 days post-treatment [clinicaltrials_resource:15431c24d7dc0a84b1b7a690baabd50c]

Adverse events, and their attribution throughout the study Up to 30 days post-treatment [clinicaltrials_resource:24ffdb36ae097f7a198a07810c912a9e]

clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]

Adverse events, and their attribution throughout the study Up to 30 days post-treatment [clinicaltrials_resource:25896581275cf113340a3ae743aa5860]

Adverse events, and their attribution throughout the study Up to 30 days post-treatment [clinicaltrials_resource:6b5f7ee246069f7979d4166b315ec1b4]

Adverse events, and their attribution throughout the study Up to 30 days post-treatment [clinicaltrials_resource:71bb3d56230f32c504f192ab1a2e5dab]

Adverse events, and their attribution throughout the study Up to 30 days post-treatment [clinicaltrials_resource:7a1ad80cd318a74e2ec04c23d2b91be4]

Adverse events, and their attribution throughout the study Up to 30 days post-treatment [clinicaltrials_resource:a93738905938b8a26707d25ab98f54d0]

Adverse events, and their attribution throughout the study Up to 30 days post-treatment [clinicaltrials_resource:ba8d7addc4bf8c9ec392492a8dc37744]

collaborator [clinicaltrials_vocabulary:collaborator]

Roswell Park Cancer Institute [clinicaltrials_resource:edb2c7b7fc53b91608536c501a86f260]

condition [clinicaltrials_vocabulary:condition]

Essential Thrombocythemia [clinicaltrials_resource:880b4d3ff8ac70ec654d3b1375eda83c]

Polycythemia Vera [clinicaltrials_resource:b424416ca4721b69bbc26262d5fcced6]

Primary Myelofibrosis [clinicaltrials_resource:c1cd7303a5c833476abf3d017fbc4385]

condition browse [clinicaltrials_vocabulary:condition-browse]

Polycythemia [clinicaltrials_resource:15b251b5cf9330b8b4374e9c162b6615]

Thrombocytosis [clinicaltrials_resource:8559a0fc1bbb59ae34aa517707437ece]

Polycythemia Vera [clinicaltrials_resource:b424416ca4721b69bbc26262d5fcced6]

Primary Myelofibrosis [clinicaltrials_resource:c1cd7303a5c833476abf3d017fbc4385]

Thrombocythemia, Essential [clinicaltrials_resource:d09a1583ee79feba648a8ad2ad9952ad]

condition mesh [clinicaltrials_vocabulary:condition-mesh]

Polycythemia [clinicaltrials_resource:15b251b5cf9330b8b4374e9c162b6615]

Thrombocytosis [clinicaltrials_resource:8559a0fc1bbb59ae34aa517707437ece]

Polycythemia Vera [clinicaltrials_resource:b424416ca4721b69bbc26262d5fcced6]

Primary Myelofibrosis [clinicaltrials_resource:c1cd7303a5c833476abf3d017fbc4385]

Thrombocythemia, Essential [clinicaltrials_resource:d09a1583ee79feba648a8ad2ad9952ad]

country [clinicaltrials_vocabulary:country]

United States [clinicaltrials_resource:f253efe302d32ab264a76e0ce65be769]

detailed description [clinicaltrials_vocabulary:detailed-description]

PRIMARY OBJECTIVES: ...... ry 4 months for 1 year.

http://www.w3.org/2001/XMLSchema#string

download date [clinicaltrials_vocabulary:download-date]

ClinicalTrials.gov processed this data on August 10, 2015

http://www.w3.org/2001/XMLSchema#string

eligibility [clinicaltrials_vocabulary:eligibility]

eligibility for clinicaltrials:NCT01014546 [clinicaltrials_resource:a8d524cf8baba745fc9edf1b7409eeb6]

firstreceived date [clinicaltrials_vocabulary:firstreceived-date]

2009-11-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

has expanded access [clinicaltrials_vocabulary:has-expanded-access]

http://www.w3.org/2001/XMLSchema#string

intervention [clinicaltrials_vocabulary:intervention]

Ascorbic Acid [clinicaltrials_resource:2fde93667d81bc5bba1b3eb51b259909]

Arsenic Trioxide [clinicaltrials_resource:4353dfffe3b527cf9322dbef3bb1b0f6]

Pharmacological Study [clinicaltrials_resource:87e887e65377862184051063b281a774]

Laboratory Biomarker Analysis [clinicaltrials_resource:daa4031d447bbf3b786ee3591b84581f]

intervention browse [clinicaltrials_vocabulary:intervention-browse]

Ascorbic Acid [clinicaltrials_resource:6f276e8079ee87584f66bee05901e7ab]

Arsenic trioxide [clinicaltrials_resource:8dca652da1729a15af2a3a5ecc31680d]

Vitamins [clinicaltrials_resource:cf51badbc1ec9808ff078dbe5f86ca9a]

is fda regulated [clinicaltrials_vocabulary:is-fda-regulated]

Yes

http://www.w3.org/2001/XMLSchema#string

is section 801 [clinicaltrials_vocabulary:is-section-801]

http://www.w3.org/2001/XMLSchema#string

lastchanged date [clinicaltrials_vocabulary:lastchanged-date]

2015-07-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

lead sponsor [clinicaltrials_vocabulary:lead-sponsor]

Roswell Park Cancer Institute [clinicaltrials_resource:edb2c7b7fc53b91608536c501a86f260]

location [clinicaltrials_vocabulary:location]

Roswell Park Cancer Institute [clinicaltrials_resource:d6427fac231c9654321afd23e525df6d]

nct id [clinicaltrials_vocabulary:nct-id]

NCT01014546

http://www.w3.org/2001/XMLSchema#string

number of arms [clinicaltrials_vocabulary:number-of-arms]

http://www.w3.org/2001/XMLSchema#integer

official title [clinicaltrials_vocabulary:official-title]

A Phase I Study of Oral Arseni ...... d in Adults With Myelofibrosis

http://www.w3.org/2001/XMLSchema#string

org study id [clinicaltrials_vocabulary:org-study-id]

I 154609

http://www.w3.org/2001/XMLSchema#string

overall official [clinicaltrials_vocabulary:overall-official]

Meir Wetzler [clinicaltrials_resource:76e5258551a144c81c7407b9af074647]

overall status [clinicaltrials_vocabulary:overall-status]

Active, not recruiting [clinicaltrials_resource:a6bc1606956390bcd6a391faced78809]

oversight [clinicaltrials_vocabulary:oversight]

United States: Food and Drug Administration [clinicaltrials_resource:be4cea82cb21bbda79c939a4d720315b]

phase [clinicaltrials_vocabulary:phase]

Phase 1 [clinicaltrials_resource:ee4650e51426c7487977eeea8e7e6850]

primary completion date [clinicaltrials_vocabulary:primary-completion-date]

2015-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

responsible party [clinicaltrials_vocabulary:responsible-party]

[clinicaltrials_resource:dbd41868ee618d3e64daa1adf8c3a8a0]

secondary id [clinicaltrials_vocabulary:secondary-id]

NCI-2009-01660

http://www.w3.org/2001/XMLSchema#string

source [clinicaltrials_vocabulary:source]

Roswell Park Cancer Institute [clinicaltrials_resource:edb2c7b7fc53b91608536c501a86f260]

start date [clinicaltrials_vocabulary:start-date]

2010-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

study design [clinicaltrials_vocabulary:study-design]

clinicaltrials:NCT01014546 study design [clinicaltrials_resource:8acebb3d23e875cc4b6d5c6849eac9af]

study type [clinicaltrials_vocabulary:study-type]

Interventional [clinicaltrials_resource:843ac00ae5d0b7c7defb84fb42c2ce31]

url [clinicaltrials_vocabulary:url]

NCT01014546

verification date [clinicaltrials_vocabulary:verification-date]

2015-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

identifier

clinicaltrials:NCT01014546

http://www.w3.org/2001/XMLSchema#string

title

Arsenic Trioxide With or Without Ascorbic Acid in Treating Patients With Myelofibrosis

@en

inDataset

clinicaltrials_resource:bio2rdf.dataset.clinicaltrials.R3

type

Clinical Study [clinicaltrials_vocabulary:Clinical-Study]

clinicaltrials resource [clinicaltrials_vocabulary:Resource]

label

Arsenic Trioxide With or Witho ...... s [clinicaltrials:NCT01014546]

@en